Navitoclax, a pre-existing anti-cancer medication designed to target inactive senescent cells, may offer a solution to alleviating lower back pain, according to recent research. The study, released as a Reviewed Preprint in eLife, enhances our comprehension of the role played by senescent osteoclasts—cells responsible for breaking down and eliminating damaged bone tissue—in the formation of lower back pain, a condition affecting 8 in 10 individuals at some stage in their lives.
Osteoclasts participate in the natural process of bone remodeling and maintenance by resorbing and breaking down bone tissue. When these cells enter a senescent state, their functionality is compromised, potentially leading to issues in bone maintenance and repair.
Lead author Dayu Pan, Johns Hopkins University School of Medicine in the US, elucidates, “Prior studies have demonstrated that senescence contributes to age-related musculoskeletal conditions such as osteoporosis, and the removal of senescent cells from degenerated vertebral discs restores the intervertebral disc structure.”
News in Same Category
Tobacco-Related Cancers Claim 1.3 Million Lives Yearly in India and Six Other Countries
Rising Type 2 Diabetes Cases in Children Linked to Changing Lifestyles
Israeli Military’s Attacks on Gaza Healthcare Spark Global Outcry
Tragic Measles Death in Malappuram Highlights Urgent Vaccination Need
Study Links Human Behavior to COVID-19 Evolution
Genetic Screening Offers Vital Treatment Insights for Familial Hypercholesterolemia
Soda Intake in Youth Linked to Future Alcohol Use and Cognitive Effects
Raw Meat Diet Increases Risk of Antibiotic-Resistant E. coli in Dogs
Combination Therapy Shows Promise for Pediatric Glioma Treatment in BRAF-Mutated Cases
AIIMS Delhi Adds 63 Free Drugs for Low-Income Patients
